Skip to content

{ Tag Archives } Staphylococcus Aureus

Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus [...]

Bookmark and Share Also tagged , , , , , , , , , , , , , , , , , ,

Theravance And Astellas Announce FDA Approval Of VIBATIVTM (telavancin) For The Treatment Of Complicated Skin And Skin Structure Infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Bookmark and Share Also tagged , , , , , , , , , , , , , , , , , ,

What Is Impetigo? What Causes Impetigo?

Impetigo is a highly contagious skin infection that is most common in children, it is caused by the staphylococcus aureus, or more rarely streptococcus pyogenes bacteria. Children account for about 70% of all cases. The first sign of impetigo is a patch of red, itchy skin. In colder countries most cases of impetigo are caused [...]

Bookmark and Share Also tagged , , , ,